用毕赤酵母组成型分泌表达Canstatin-N

目的:用毕赤酵母的GAP启动子调控组成型表达Canstatin-N。方法:将canstatin-N基因重组于毕赤酵母表达载体pGAP9K的多克隆位点获得pGAP9K-can-N。用电转法将pGAP9K-can-N转化毕赤酵母GS115。筛选高G418抗性的克隆作为工程菌GS115(pGAP9K-can-N)。发酵GS115(pGAP9K-can-N)分泌表达Canstatin-N,用离子交换法纯化目标蛋白。结果:以葡萄糖为碳源,发酵48h分泌表达人血管能抑素蛋白56 mg/L。结论:用毕赤酵母的GAP启动子调控组成型表达的人血管能抑素蛋白具有诱发血管内皮细胞凋亡的生物活性。     

用毕赤酵母的GAP启动子调控表达L-阿拉伯糖异构酶

应用PCR从大肠杆菌基因组中扩增L-阿拉伯糖异构酶基因,用EcoR I和Not I双酶切将其克隆进P.pastoris表达载体,获得重组表达载体pGAP9K-L-ai。通过电转法将pGAP9K—L-ai转化毕赤酵母GS115,筛选高G418抗性和高表达L-阿拉伯糖异构酶的重组工程菌。用葡萄糖作为碳源在摇瓶中发酵48 h,表达重组L-ai 53 mg/L。用毕赤酵母的GAP启动子调控表达的重组L-ai具有异构D-半乳糖生成D-塔格糖的生物学活性。     

用GAP启动子在Pichia pastoris GS115中组成型表达鼠灰链霉菌腺苷酸脱氨酶

【目的】构建产AMP脱氨酶的重组毕赤酵母(Pichia pastoris GS115)菌株,并初步优化其发酵条件。【方法】以鼠灰链霉菌(Streptomyces murinus)基因组为模板PCR扩增获得腺苷酸脱氨酶基因AMPD,以pGAP9K为载体构建重组表达质粒pGAP9K-AMPD并通过电转化法转入Pichia pastoris GS115,筛选转化子对其酶活进行测定,并初步优化其发酵条件。【结果】构建了毕赤酵母重组菌,通过分光光度法测定,显示重组菌有明显的酶活;初步优化发酵条件为:该重组菌最适发酵培养基为:甘油2%,蛋白胨2%,酵母膏1%,KH2PO40.5%,MgSO4·7H2O0.05%,pH 6.0;发酵条件为:接种龄24 h,转接量3%,30°C﹑200 r/min培养96 h,取发酵上清液测定酶活,重组菌腺苷酸脱氨酶酶活达到2 230±60 U/mL。【结论】构建了一株产AMP脱氨酶活性较高的重组毕赤酵母菌株,并通过优化发酵条件使其酶活达到2 230±60 U/mL。为AMP脱氨酶工业化生产奠定了一定的基础。     

黑曲霉阿魏酸酯酶在毕赤酵母中的组成型表达

【目的】实现黑曲霉来源的阿魏酸酯酶在毕赤酵母(Pichia pastoris GS115)中的组成型表达。【方法】以黑曲霉(Aspergillus niger)基因组为模板,经重叠延伸PCR扩增得到阿魏酸酯酶基因(AnfaeA),将其与载体pGAP9K相连,构建重组表达载体p GAP9KAnfae A,经SalI线性化后电转入毕赤酵母GS115中,得到重组菌株。高效液相色谱法测定发酵液中阿魏酸酯酶活力,并对重组菌进行了发酵优化。【结果】克隆得到783 bp的阿魏酸酯酶编码基因并实现了其在毕赤酵母中的组成型表达。重组菌发酵84 h后,上清液中酶活达5.72±0.10 U/m L。重组酶(reAnfaeA)经分离纯化后比酶活为59.75 U/mg,大小约为40 k D。发酵优化结果为:葡萄糖40.0 g/L,蛋白胨10.0 g/L,酵母膏30.0 g/L,CaCO_3 0.2 g/L,种龄28 h,接种量3%(体积比),装液量50 m L/250 m L。在此条件下发酵培养,酶活达15.60±0.23 U/m L。【结论】阿魏酸酯酶在毕赤酵母中的组成型表达,对研究毕赤酵母组成型表达系统和阿魏酸酯酶的发酵生产具有一定的借鉴意义。     

通过非甲醇诱导游离型表达载体改善毕赤酵母中β-半乳糖苷酶表达

β-半乳糖苷酶是一种重要的食品工业用酶,目前主要通过毕赤酵母甲醇诱导型表达系统进行生产,但甲醇的使用存在火灾、残留毒性等安全隐患,已逐渐成为食品工业用酶生产中备受关注的问题之一.为满足β-半乳糖苷酶安全生产的需要,本研究利用强组成型启动子PGCW14和源自酵母的自我复制序列PARS构建了一种新型非甲醇诱导游离型表达载体pGCW14ZαA-PARS,并且在此基础上分别构建了非甲醇诱导游离型重组表达菌株KM71/pGCW14ZαA-PARS-Aoβ-GAL,用以改善米曲霉Aspergillus Oryzae RIB40(ATCC42149)来源的β-半乳糖苷酶基因(Aoβ-GAL)在毕赤酵母中的表达.实验结果表明,该非甲醇诱导游离型表达载体在毕赤酵母中传代培养90代后仍保持83.22％的遗传稳定性,完全能够满足工业上大规模生产的需要.在10％流速补充碳源的条件下,非甲醇诱导游离表达菌株KM71/pGCW14ZαA-PARS-Aoβ-GAL经高密度发酵的最高酶活性和比活性分别为126.4 U/mL和26.2 U/mg,分别是传统甲醇诱导型表达菌株KM71/pPIC9k-Aoβ-GAL的1.94倍和3.12倍,且发酵周期缩短了36h.可见,本研究构建的非甲醇诱导游离型表达载体可有效改善β-半乳糖苷酶在毕赤酵母中的表达,且在食品工业用酶的安全、高效工业化生产中具有一定的应用前景.     

脊髓灰质炎2型病毒样颗粒在毕赤酵母内的表达与鉴定

目的构建可稳定表达脊髓灰质炎病毒(poliovirus,PV)类病毒颗粒(virus-like particles,VLPs)的整合型重组毕赤酵母,鉴定PV VLPs在毕赤酵母细胞中的表达及组装情况。方法根据毕赤酵母密码子偏好性优化salk株II型P1和3CD基因并连接到p Pic ZA载体,构建p Pic ZA-P1-3CD表达载体;用Bgl II线性化p Pic ZA-P1-3CD载体,电转至毕赤酵母GS115中。通过Zeocin抗性筛选获得整合型重组毕赤酵母,随后用高浓度Zeocin抗性筛选得到高表达菌株。甲醇诱导后,用Western Blot检测目的蛋白表达;蔗糖密度梯度离心纯化PV VLPs并进行透射电镜观察。结果成功构建p Pic ZA-P1-3CD表达载体,获得PV VLPs重组毕赤酵母。Western Blot在重组毕赤酵母裂解上清中检测到目的蛋白的表达;蔗糖密度梯度离心纯化后,在透射电镜中观察到直径为30 nm左右的VLPs,其形态与天然的PV颗粒相似。结论成功构建PV-2型VLPs的整合型重组酵母系统,并在毕赤酵母中组装形成了VLPs,为酵母表达系统中PV VLPs疫苗的研制奠定了基础。     

特异腐质霉中性内切葡聚糖酶Ⅱ基因的克隆及表达

利用RT-PCR的方法,以特异腐质霉（Humicola insolerts）H31-3总RNA为模板,克隆到中性内切葡聚糖酶Ⅱ基因egl2的cDNA,将其插入到表达载体pGAPZαA中,重组质粒经线性化,电击转化毕赤酵母（Pichia pastoris）菌株GS115,筛选到分泌表达重组EGⅡ的毕赤酵母工程菌株。SDS-PAGE检测结果表明,重组EGⅡ在酵母中得到了特异性表达,表达产物的表观分子量约为55kD,同时对工程菌株的发酵条件和重组EGⅡ的性质进行了初步研究。     

组成型表达重组人C-反应蛋白的毕赤酵母菌株构建

目的:构建组成型表达重组人C-反应蛋白(Recombinant human C-reactive protein,rhCRP)的毕赤酵母工程菌株,表达、纯化rhCRP并鉴定其免疫反应性。方法:将设计合成的rhCRP基因克隆到表达载体pGAPZαA上并转化至毕赤酵母X-33中进行组成型分泌表达,通过His亲和层析柱纯化rhCRP。分别采用SDS-PAGE、Western blot和间接ELISA法检测目的蛋白并鉴定其免疫反应性。结果:重组表达载体pGAPZαA/rhCRP经酶切及DNA测序鉴定构建成功。重组毕赤酵母工程菌株成功组成型表达23kDa的rhCRP,27h即达到最大表达水平,表达量约3mg/L。经一步分离纯化获得纯度为96.58%的rhCRP,经间接ELISA检测表明其具有免疫反应性。结论:成功构建了组成型分泌表达rhCRP的毕赤酵母菌株,为进一步自主研发人CRP检测试剂奠定了基础。     

FAD依赖的葡萄糖脱氢酶多拷贝毕赤酵母菌株的构建及高效表达

通过体外多拷贝构建实现FAD依赖的葡萄糖脱氢酶(FAD-GDH)在毕赤酵母(Pichia pastoris)X33菌株中的高效表达。将前期构建的经密码子偏好性优化FAD-GDH基因插入到pPICZαA质粒中，通过同尾酶法酶切酶连构建含1～4个表达盒的重组表达质粒，分别电转至毕赤酵母X33中，成功筛选到各种重组菌株。qRT-PCR测定结果表明，载体所含的表达盒数目与嵌合进毕赤酵母基因组中的GDH基因拷贝数之间存在正相关关系。重组菌在试管水平用甲醇诱导72 h,酶活达到最高，其中4拷贝的转化子表达水平最高；选择1拷贝和4拷贝转化子进行10 L发酵罐扩大培养，1拷贝菌株诱导108 h酶活达到最高697.125 U/mL,4拷贝菌株诱导132 h酶活达到最高1 063.279 U/mL,比1拷贝酶活提高52.52%。结果表明通过增加目的基因拷贝数策略有助于提高FAD-GDH的表达量，为其进一步扩大生产提供参考。     

硫色曲霉β-甘露聚糖酶在毕赤酵母中的组成型分泌表达

目的：构建硫色曲霉β-甘露聚糖酶的毕赤酵母组成型分泌表达菌株,研究重组菌株的产酶水平。方法：EcoR I／Xba I双酶切质粒pPIC-mann-opt,琼脂糖凝胶电泳、回收目的基因片段后,与组成型毕赤酵母表达载体pGAPzαA连接,转化大肠杆菌,经筛选获得含有pGAP-mann-opt的重组克隆;提取pGAP-mann-opt,用限制性内切酶BspH I线性化后,转化毕赤酵母X-33感受态细胞,进行Zeocin抗性筛选和PCR鉴定。结果：获得了重组菌株,重组菌株在YPD培养基中摇瓶发酵24h,上清液酶活达到343U／mL,产酶蛋白约为1.0mg／mL。结论：构建的硫色曲霉β-甘露聚糖酶组成型表达菌株具有较好的应用前景。     

Tumor-specific gene expression patterns with gene expression profiles

Gene expression profiles of 14 common tumors and their counterpart normal tissues were analyzed with machine learning methods to address the problem of selection of tumor-specific genes and analysis of their differential expressions in tumor tissues. First, a variation of the Relief algorithm, "RFE_Relief algorithm" was proposed to learn the relations between genes and tissue types. Then, a support vector machine was employed to find the gene subset with the best classification performance for distinguishing cancerous tissues and their counterparts. After tissue-specific genes were removed, cross validation experiments were employed to demonstrate the common deregulated expressions of the selected gene in tumor tissues. The results indicate the existence of a specific expression fingerprint of these genes that is shared in different tumor tissues, and the hallmarks of the expression patterns of these genes in cancerous tissues are summarized at the end of this paper.     

Tumor-specific gene expression patterns with gene expression profiles

Gene expression profiles of 14 common tumors and their counterpart normal tissues were analyzed with machine learning methods to address the problem of selection of tumor-specific genes and analysis of their differential expressions in tumor tissues. First, a variation of the Relief algorithm, “RFE_Relief algorithm” was proposed to learn the relations between genes and tissue types. Then, a support vector machine was employed to find the gene subset with the best classification performance for distinguishing cancerous tissues and their counterparts. After tissue-specific genes were removed, cross validation experiments were employed to demonstrate the common deregulated expressions of the selected gene in tumor tissues. The results indicate the existence of a specific expression fingerprint of these genes that is shared in different tumor tissues, and the hallmarks of the expression patterns of these genes in cancerous tissues are summarized at the end of this paper.     

High-level expression of full-length antibodies using trans-complementing expression vectors

Recombinant antibodies are increasingly used as therapeutics for a wide variety of diseases. Generation of cell lines expressing high levels of recombinant antibody typically requires labor-intensive cloning and screening steps. We describe a mammalian expression system for the high-level production of full-length antibody molecules. It has been shown that the dihydrofolate reductase (DHFR) selectable marker can be divided into two fragments that, with the aid of a leucine zipper, can re-associate to form an active molecule. Using bicistronic vectors, we linked the expression of each antibody chain to the expression of a DHFR fragment. Survival in selective media requires expression of both DHFR fragments that, by virtue of these vectors, also selects for the expression of both antibody chains. Initial pools produced 5 microg of Ab/10(6) cells/d (qP = microg/10(6) cells/d). Expression of each antibody chain in conjunction with a portion of DHFR also leads to concurrent amplification of both antibody chains in the presence of methotrexate, a DHFR inhibitor, and results in a two- to fivefold increase in antibody production with basal qPs ranging from 10-25 ug/10(6) cells/d. Shake-flask cultures of amplified pools produced up to 600 mg/L of antibody in 7 days. This system allows for rapid generation of antibodies without cloning and greatly simplifies selection of cell lines for the production of potential antibody therapeutics.